Trospium chloride is an antispasmodic antimuscarinic agent marketed as SANCTURA for overactive bladder symptoms including urge urinary incontinence, urgency, and urinary frequency. It is a quaternary ammonium antimuscarinic compound and has been FDA approved in the U.S. since 2004.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07063342 |
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants |
RECRUITING | PHASE1 |
| NCT05880862 |
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
| NCT03709992 |
Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: |
SUSPENDED | NA |
| NCT02831231 |
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium |
COMPLETED | PHASE1 |
| NCT01922115 |
The Effect of Anticholinergics on Cognitive Function in the Elderly |
COMPLETED | PHASE4 |
| NCT01178827 |
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial |
COMPLETED | PHASE4 |
| NCT01166438 |
Anticholinergic vs. Botox Comparison Study |
COMPLETED | PHASE3 |
| NCT01089751 |
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily |
COMPLETED | PHASE4 |
| NCT00863551 |
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial |
COMPLETED | PHASE4 |
